News | January 27, 2022
Moderna working on Omicron-specific booster candidate
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
The country is sixth among the most affected countries by active cases
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
It provides Covid-19 detection and Omicron surveillance in less than two hours
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
In-house wet testing with live Omicron virus demonstrated that the Antigen test detects the Omicron variant with comparable sensitivity to other variants
The study will be published on the pre-print server, medRXiv, shortly
Recent Study by Columbia University finds Mylab’s CoviSelf can detect the Omicron variant successfully
Subscribe To Our Newsletter & Stay Updated
